Author Index for Volume 9

Abel UR, 149
Ahlquist RP, 137
Ahmann DL, 107
Aldridge J, 189

Bernstein F, 23
Boissel J-P, 386
Bristol DR, 206
Bruce RA, 137
Byar DP, 82, 119

Chalmers TC, 85, 137
Chesler E, 189
Clifford C, 119
Collins JF, 47
Conn HO, 88
Copeland J, 189
Cramer, JA, 47

DeMots H, 189
Dickersin K, 76, 85
Doherty J, 189

Edler L, 149
Emery R, 189

Floten S, 189
Frantz ID, 137

Gannon C, 19
Goldman S, 119
Goldman S, 189
Goldwater WH, 137
Goodman S, 387
Gorbach SL, 119
Greenberg BG, 137
Greenwald P, 119
Gurdjian ES, 137

Haakenson C, 189
Harker LA, 189
Hawkins BS, 19, 64, 103, 152, 212
Henderson M, 119
Henderson WG, 189
Hewitt P, 85
Hilsenbeck SG, 177
Holt J, 189
Hosking JD, 19
Hsu Y-L, 189

Ingle JN, 107
Insull W, 119
Iverson D, 119

James KE, 19
Josa M, 189

Kimball AW, 6
Kirklin J, 189
Kritchevsky D, 137

Lachin JM, 287, 289, 312, 327
Lancaster L, 189
Luckey EH, 137

Markowitz JA, 19
Masud Z, 189
Matts JP, 327
Mattson RH, 47
McGill HC, 137
Meinert CL, 1, 97
Montoya A, 189
Moores W, 189
Morgan TM, 11
Moritz T, 189
Mowery RL, 19
Mueller CB, 137

Ovitt T, 189

Pacold I, 189
Parikh D, 189
Peace KE, 383
Piantadosi S, 82
Poynard T, 88
Prentice R, 119

Read R, 189

Sako Y, 189
Schaid DJ, 107
Self S, 119
Sethi G, 189
Shabetai R, 189
Sharma GVRK, 189
Sheppard L, 119
Souchek J, 189
Stallones RA, 137
Swan HJC, 137

Thompson D, 119

Urban N, 119
Urbanski S, 189

Wu MC, 32
Wieand S, 107

Zadina K, 189

0197-2456/1988/$3.50
© Elsevier Science Publishing Co., Inc. 1988
655 Avenue of the Americas, New York, New York 10010

Author Index for Volume 9

Abel UR, 149
Ahlquist RP, 137
Ahmann DL, 107
Aldridge J, 189

Bernstein F, 23
Boissel J-P, 386
Bristol DR, 206
Bruce RA, 137
Byar DP, 82, 119

Chalmers TC, 85, 137
Chesler E, 189
Clifford C, 119
Collins JF, 47
Conn HO, 88
Copeland J, 189
Cramer, JA, 47

DeMots H, 189
Dickersin K, 76, 85
Doherty J, 189

Edler L, 149
Emery R, 189

Floten S, 189
Frantz ID, 137

Gannon C, 19
Goldman S, 119
Goldman S, 189
Goldwater WH, 137
Goodman S, 387
Gorbach SL, 119
Greenberg BG, 137
Greenwald P, 119
Gurdjian ES, 137

Haakenson C, 189
Harker LA, 189
Hawkins BS, 19, 64, 103, 152, 212
Henderson M, 119
Henderson WG, 189
Hewitt P, 85
Hilsenbeck SG, 177
Holt J, 189
Hosking JD, 19
Hsu Y-L, 189

Ingle JN, 107
Insull W, 119
Iverson D, 119

James KE, 19
Josa M, 189

Kimball AW, 6
Kirklin J, 189
Kritchevsky D, 137

Lachin JM, 287, 289, 312, 327
Lancaster L, 189
Luckey EH, 137

Markowitz JA, 19
Masud Z, 189
Matts JP, 327
Mattson RH, 47
McGill HC, 137
Meinert CL, 1, 97
Montoya A, 189
Moores W, 189
Morgan TM, 11
Moritz T, 189
Mowery RL, 19
Mueller CB, 137

Ovitt T, 189

Pacold I, 189
Parikh D, 189
Peace KE, 383
Piantadosi S, 82
Poynard T, 88
Prentice R, 119

Read R, 189

Sako Y, 189
Schaid DJ, 107
Self S, 119
Sethi G, 189
Shabetai R, 189
Sharma GVRK, 189
Sheppard L, 119
Souchek J, 189
Stallones RA, 137
Swan HJC, 137

Thompson D, 119

Urban N, 119
Urbanski S, 189

Wu MC, 32
Wieand S, 107

Zadina K, 189

0197-2456/1988/$3.50
© Elsevier Science Publishing Co., Inc. 1988
655 Avenue of the Americas, New York, New York 10010

Subject Index for Volume 9

ACCIDENTAL BIAS
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

ADHERENCE
Can Categorization of Patient Background Problems Be Used to Determine Early Termination in a Clinical Trial?, 47

ANALYSIS
Properties of Simple Randomization in Clinical Trials, 312

ANTIPLATELET THERAPY
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting, 189

ARC-SINE TRANSFORMATION
A One-Sided Interim Analysis with Binary Outcomes, 206

BINARY OUTCOMES
A One-Sided Interim Analysis with Binary Outcomes, 206

BLOCKED-STRATIFIED ANALYSIS
Properties of Permuted-Block Randomization in Clinical Trials, 327

BOOK REVIEWS
Clinimetrics by Feinstein AR, 163
Clinical Epidemiology by Fletcher RH, Fletcher SW, and Wagner EH, 389
Guide to Clinical Interpretation of Data by Spilker B, 93
Guide to Planning and Managing Multiple Clinical Studies by Spilker B, 166
Statistical Tables for the Design of Clinical Trials by Machin D and Campbell M, 165
Statistics in Medicine (Volume 6, Number 3, published by John Wiley & Sons), 167
Using and Understanding Medical Statistics by Matthews DE and Farewell VT, 91

BREAST CANCER
Statistical Design of the Women's Health Trial, 119

CASE-COHORT SAMPLING
Statistical Design of the Women's Health Trial, 119

CLINICAL TRIALS
A Proposal for Registering Clinical Trials, Letter to the Editor, 82
Analysis of Duration of Response: A Problem of Oncology Trials, 11
Can Categorization of Patient Background Problems Be Used to Determine Early Termination in a Clinical Trial?, 47
Measures of and Tests for Net Improvement in Clinical Trials, 6
Report from a Workshop: Archives for Data and Documents from Completed Clinical Trials, 19
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials, 76
Response to Hewitt et al: Retrieval of Randomized Clinical Trials in Liver Disease, Letter to the Editor, 88
The Retrieval of Randomized Clinical Trials in Liver Diseases from the Medical Literature: Manual versus MEDLARS Searches, 23
Toward Prospective Registration of Clinical Trials, 1

CLINICAL TRIAL REGISTERS
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials, 76

CLUSTER SAMPLING
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting, 189

COMPLETE BINOMIAL
Properties of Simple Randomization in Clinical Trials, 312

© Elsevier Science Publishing Co., Inc. 1988
655 Avenue of the Americas, New York, New York 10010

0197-2456/1988/$3.50

COMPLIANCE
Can Categorization of Patient Backgound Problems Be Used to Determine Early Termination in a Clinical Trial?, 47

DIETARY FAT
Statistical Design of the Women's Health Trial, 119

DISEASE PREVENTION
Statistical Design of the Women's Health Trial, 119

EARLY TERMINATION
Early Termination of a Phase II Clinical Trial, 177

EPILEPSY
Can Categorization of Patient Background Problems Be Used to Determine Early Termination in a Clinical Trial?, 47

HEALTH STATUS
Measures of and Tests for Net Improvement in Clinical Trials, 6

HEART SPECIAL PROJECT COMMITTEE
Organization, Review, and Administration of Cooperative Studies (Greenberg Report): A Report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967, 137

INFERENCE
Statistical Properties of Randomization in Clinical Trials, 289

INFORMATION SYSTEMS
The Retrieval of Randomized Clinical Trials in Liver Diseases from the Medical Literature: Manual versus MEDLARS Searches, 23

INTERIM ANALYSIS
A One-Sided Interim Analysis with Binary Outcomes, 206

INTRABLOCK CORRELATION
Properties of Permuted-Block Randomization in Clinical Trials, 327

LINEAR RANDOM EFFECT
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry, 32

LITERATURE
Perusing the Literature, 64, 152, 212

MANTEL-HAENSZEL TEST
Properties of Permuted-Block Randomization in Clinical Trials, 327

MEDLARS-MEDLINE
More on MEDLINE Searches, Letter to the Editor, 85

MEDLARS-MEDLINE INFORMATION SYSTEM
The Retrieval of Randomized Clinical Trials in Liver Diseases from the Medical Literature: Manual versus MEDLARS Searches, 23

META-ANALYSIS
A Pitfall in the Meta-analysis of Hazard Ratios, 149
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials, 76

MISSING DATA
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

NATIONAL INSTITUTES OF HEALTH
NIH Multicenter Investigator-Initiated Trials: An Endangered Species?, 97
The National Institutes of Health and their Sponsorship of Clinical Trials, 103

NET IMPROVEMENT
Measures of and Tests for Net Improvement in Clinical Trials, 6

PERMUTATION TESTS
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

PERMUTED-BLOCK DESIGN
Properties of Permuted-Block Randomization in Clinical Trials, 327

PHASE II ANTICANCER AGENTS
A Design for Phase II Testing of Anticancer Agents within a Phase III Clinical Trial, 107

PHASE II TRIAL
Early Termination of a Phase II Clinical Trial, 177

PHASE III SURVIVAL COMPARISON
A Design for Phase II Testing of Anticancer Agents within a Phase III Clinical Trial, 107

PLATELET INHIBITORS
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting, 189

POPULATION MODELS
Statistical Properties of Randomization in Clinical Trials, 289

PREDICTIVE PROBABILITY
Early Termination of a Phase II Clinical Trial, 177

PROBIT MISSING PROCESS
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry, 32

PUBLICATION BIAS
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Trials at the Eighth Annual Meeting of the Society for Clinical Trials, 76

RADIO ESTIMATE
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting, 189

RANDOM ALLOCATION
Properties of Simple Randomization in Clinical Trials, 312
The Retrieval of Randomized Clinical Trials in Liver Diseases from the Medical Literature: Manual versus MEDLARS Searches, 23

RANDOMIZATION
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Randomization in Clinical Trials: Foreword, 287
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

RANDOMIZED DESIGN
A Design for Phase II Testing of Anticancer Agents within a Phase III Clinical Trial, 107

RATES OF CHANGE
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry, 32

RESEARCH DESIGN
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials, 76

RIGHT CENSORED MISSING VALUES
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry, 32

SAMPLE SIZE DETERMINATION FOR CLINICAL TRIALS
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry, 32

SELECTION BIAS
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

SOCIETY FOR CLINICAL TRIALS
Abstracts: Ninth Annual Meeting of the Society for Clinical Trials, 242
Final Program: Ninth Annual Meeting of the Society for Clinical Trials, 224
Society for Clinical Trials Officers, Board of Directors, Program Committee Chairman, and Secretariat, 223

STOCHASTIC CURTAILING
Early Termination of a Phase II Clinical Trial, 177

STRATIFIED ANALYSIS
Properties of Permuted-Block Randomization in Clinical Trials, 327
Properties of Simple Randomization in Clinical Trials, 312
Statistical Properties of Randomization in Clinical Trials, 289

SURVIVAL ANALYSIS
Analysis of Duration of Response: A Problem of Oncology Trials, 11

TWO-TAILED TESTS
One-Sided or Two-Sided *p* Values?, Letter to the Editor, 387
Some Thoughts on One-Tailed Tests, Letter to the Editor, 383
Some Thoughts on Two-Tailed Tests (and Two-Sided Designs), Letter to the Editor, 385

VEIN GRAFT PATENCY
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting, 189

VISUAL ACTIVITY
Measures of and Tests for Net Improvement in Clinical Trials, 6

Controlled Clinical Trials

DESIGN, METHODS, AND ANALYSIS

Official Journal of the Society for Clinical Trials

Volume 9, 1988

Contents

CURTIS L. MEINERT
Editorial: Toward Prospective Registration of Clinical Trials 1

A. W. KIMBALL
Measures of and Tests for Net Improvement in Clinical Trials 6

TIMOTHY M. MORGAN
Analysis of Duration of Response: A Problem of Oncology Trials 11

BARBARA S. HAWKINS, CLARA GANNON, JAMES D. HOSKING, KENNETH E. JAMES, JAN A. MARKOWITZ, and RICHARD L. MOWERY
Report from a Workshop: Archives for Data and Documents from Completed Clinical Trials 19

FRAN BERNSTEIN
The Retrieval of Randomized Clinical Trials in Liver Diseases from the Medical Literature: Manual versus MEDLARS Searches 23

MARGARET C. WU
Sample Size for Comparison of Changes in the Presence of Right Censoring Caused by Death, Withdrawal, and Staggered Entry 32

JOYCE A. CRAMER, JOSEPH F. COLLINS, and RICHARD H. MATTSON
Can Categorization of Patient Background Problems Be Used to Determine Early Termination in a Clinical Trial? 47

BARBARA S. HAWKINS
Perusing the Literature 64

KAY DICKERSIN
Report from the Panel on The Case for Registers of Clinical Trials at the Eighth Annual Meeting of the Society for Clinical Trials 76

Letters to the Editor

STEVEN PIANTADOSI and DAVID P. BYAR
A Proposal for Registering Clinical Trials 82

PEG HEWITT, KAY DICKERSIN, and THOMAS C. CHALMERS
More on MEDLINE Searches 85

THIERRY POYNARD and HAROLD O. CONN
Response to Hewitt Et Al: Retrieval of Randomized Clinical Trials in Liver Disease 88

Book Reviews 91

Announcement 95

CURTIS L. MEINERT
Editorial: NIH Multicenter Investigator-Initiated Trials: An Endangered Species? 97

BARBARA S. HAWKINS
The National Institutes of Health and Their Sponsorship of Clinical Trials 103

DANIEL J. SCHAID, JAMES N. INGLE, SAM WIEAND, and DAVID L. AHMANN
A Design for Phase II Testing of Anticancer Agents within a Phase III Clinical Trial 107

STEVEN SELF, ROSS PRENTICE, DONALD IVERSON, MAUREEN HENDERSON, DONOVAN THOMPSON, DAVID BYAR, WILLIAM INSULL, SHERWOOD L. GORBACH, CAROLYN CLIFFORD, SUSAN GOLDMAN, NICOLE URBAN, LIANNE SHEPPARD, and PETER GREENWALD
Statistical Design of the Women's Health Trial 119

GREENBERG REPORT
Organization, Review, and Administration of Cooperative Studies: A Report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967 137

Letter to the Editor
ULRICH R. ABEL and LUTZ EDLER
A Pitfall in the Meta-analysis of Hazard Ratios 149

BARBARA S. HAWKINS
Perusing the Literature 152

Book Reviews 163

In Memoriam: Max Halperin (1917–1988) 170

Announcements 173

SUSAN GALLOWAY HILSENBECK
Early Termination of a Phase II Clinical Trial 177

W. G. HENDERSON, T. MORITZ, S. GOLDMAN, J. COPELAND, J. SOUCHEK, K. ZADINA, T. OVITT, J. DOHERTY, R. READ, E. CHESLER, Y. SAKO, L. LANCASTER, R. EMERY, G. SHARMA, M. JOSA, I. PACOLD, A. MONTOYA, D. PARIKH, G. SETHI, J. HOLT, J. KIRKLIN, R. SHABETAI, W. MOORES, J. ALDRIDGE, Z. MASUD, H. DEMOTS, S. FLOTEN, C. HAAKENSON, Y. HSU, S. URBANSKI, L. HARKER
The Statistical Analysis of Graft Patency Data in a Clinical Trial of Antiplatelet Agents following Coronary Artery Bypass Grafting 189

DAVID R. BRISTOL
A One-Sided Interim Analysis with Binary Outcomes 206

BARBARA S. HAWKINS
Perusing the Literature 212

Society for Clinical Trials: Officers, Board of Directors, Program Committee Chairman, and Secretariat 223

Final Program: Ninth Annual Meeting of the Society for Clinical Trials 224

Abstracts: Ninth Annual Meeting of the Society for Clinical Trials 242

Erratum 286

JOHN M. LACHIN
Properties of Randomization in Clinical Trials: Foreword 287

JOHN M. LACHIN
Statistical Properties of Randomization in Clinical Trials 289

JOHN M. LACHIN
Properties of Simple Randomization in Clinical Trials 312

JOHN P. MATTS and JOHN M. LACHIN
Properties of Permuted-Block Randomization in Clinical Trials 327

L.J. WEI and JOHN M. LACHIN
Properties of the Urn Randomization in Clinical Trials 345

JOHN M. LACHIN, JOHN P. MATTS, and L.J. WEI
Randomization in Clinical Trials: Conclusions and Recommendations 365

AL HALLSTROM and KATHRYN DAVIS
Imbalance in Treatment Assignments in Stratified Blocked Randomization 375

Letters to the Editor 383

Book Review 389

Announcements 391

Author Index to Volume 9 392

Subject Index to Volume 9 393

Volume Contents